{"id":32539,"date":"2020-07-28T12:07:41","date_gmt":"2020-07-28T11:07:41","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=32539"},"modified":"2021-03-18T12:23:49","modified_gmt":"2021-03-18T12:23:49","slug":"companion-diagnostics-biomarkers-2017-speakers","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/","title":{"rendered":"Companion Diagnostics & Biomarkers 2017 Speakers"},"content":{"rendered":"
\n

\n\tOur
Speakers (A-Z)
\n\t<\/h2>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alfred_Hansel_oncgnostics_BioTech_Pharma_Summit_Profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alfred_Hansel_oncgnostics_BioTech_Pharma_Summit_Profile_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alfred_Hansel_oncgnostics_BioTech_Pharma_Summit_Profile_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alfred_Hansel_oncgnostics_BioTech_Pharma_Summit_Profile_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alfred_Hansel_oncgnostics_BioTech_Pharma_Summit_Profile_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alfred_Hansel_oncgnostics_BioTech_Pharma_Summit_Profile_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alfred_Hansel_oncgnostics_BioTech_Pharma_Summit_Profile_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32597″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/alfred-hansel\/dr-alfred-hansel-2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alfred_Hansel_oncgnostics_BioTech_Pharma_Summit_Profile_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"Eberhard J. Schorr","camera":"","caption":"oncgnostics","created_timestamp":"1374494669","copyright":"Eberhard J. Schorr","focal_length":"0","iso":"0","shutter_speed":"0","title":"Dr. Alfred Hansel","orientation":"1"}” data-image-title=”Dr. Alfred Hansel” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alfred_Hansel_oncgnostics_BioTech_Pharma_Summit_Profile_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alfred_Hansel_oncgnostics_BioTech_Pharma_Summit_Profile_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAlfred Hansel\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
CEO at oncgnostics<\/h5>\n

\n\t\t\t\n\tEpigenetic markers in cancer diagnostics\n\t\t\t<\/a>\n\t<\/h3>\n\t

As CEO Dr. Hansel is responsible for business development at oncgnostics. He has long-lasting experience in project management obtained while working at several universities in Germany and abroad as well as operative experience in industrial product development, sales and marketing.<\/p>\n

The spin-off of oncgnostics is based on his research as well as works of a project group at the university hospital, which he has led.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ali_Ardakani_Novateur_Ventures_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ali_Ardakani_Novateur_Ventures_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ali_Ardakani_Novateur_Ventures_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ali_Ardakani_Novateur_Ventures_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ali_Ardakani_Novateur_Ventures_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ali_Ardakani_Novateur_Ventures_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ali_Ardakani_Novateur_Ventures_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32634″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/ali-ardakani\/ali_ardakani_novateur_ventures_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ali_Ardakani_Novateur_Ventures_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"1494102962","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Ali_Ardakani_Novateur_Ventures_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ali_Ardakani_Novateur_Ventures_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ali_Ardakani_Novateur_Ventures_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAli Ardakani\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Managing Director at Novateur Ventures Inc.<\/h5>\n

\n\t\t\t\n\tCompanion Diagnostics: a guide to cure?\n\t\t\t<\/a>\n\t<\/h3>\n\t

For the past 18 years, Ali Ardakani has been pivotal in start-up and development of several biotech companies, drugs and medical devices, for which he has raised over $100 M USD in private and grant financing.<\/p>\n

Most recently, he co-founded virtual biotech Niiki Pharma Inc in NYC, where he acquired two first-in-class oncology drugs from Europe and took them through US IND, UK CTA and Phase 1 and 2 clinical trials within 3 years.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Austin_Speier_Precision_for_Medicine_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Austin_Speier_Precision_for_Medicine_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Austin_Speier_Precision_for_Medicine_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Austin_Speier_Precision_for_Medicine_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Austin_Speier_Precision_for_Medicine_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Austin_Speier_Precision_for_Medicine_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Austin_Speier_Precision_for_Medicine_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32608″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/austin-speier\/austin_speier_precision_for_medicine_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Austin_Speier_Precision_for_Medicine_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Austin_Speier_Precision_for_Medicine_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Austin_Speier_Precision_for_Medicine_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Austin_Speier_Precision_for_Medicine_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAustin Speier\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President, Emerging Technologies at Precision for Medicine<\/h5>\n

\n\t\t\t\n\tIntegrating Digital Medicine into a Biomarker Strategy\n\t\t\t<\/a>\n\t<\/h3>\n\t

Austin is Vice President, Emerging Technologies at Precision for Medicine, where he specializes in the design and execution of to-market clinical and regulatory strategies for innovative, first-in-class diagnostics, digital health and medical device technologies.<\/p>\n

Professional interests include personalized medicine, advanced diagnostics, mobile and digital health, bioinformatics, deep learning, advanced study designs, preventative and integrated care, user experience\/product design, and branding and communicating innovation.<\/p>\n\t\t\t\t\t\t\t\"\"\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Birgitte_Booij_SpinChip_Diagnostics_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Birgitte_Booij_SpinChip_Diagnostics_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Birgitte_Booij_SpinChip_Diagnostics_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Birgitte_Booij_SpinChip_Diagnostics_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Birgitte_Booij_SpinChip_Diagnostics_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Birgitte_Booij_SpinChip_Diagnostics_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Birgitte_Booij_SpinChip_Diagnostics_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32572″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/birgitte-booij\/birgitte_booij_spinchip_diagnostics_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Birgitte_Booij_SpinChip_Diagnostics_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"2.2","credit":"","camera":"NIKON D810","caption":"","created_timestamp":"1485337278","copyright":"","focal_length":"85","iso":"64","shutter_speed":"0.005","title":"","orientation":"1"}” data-image-title=”Birgitte_Booij_SpinChip_Diagnostics_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Birgitte_Booij_SpinChip_Diagnostics_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Birgitte_Booij_SpinChip_Diagnostics_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tBirgitte Booij\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President Product and Business development at SpinChip Diagnostics<\/h5>\n

\n\t\t\t\n\tMoving Dx testing within precision medicine to the Point of Care\n\t\t\t<\/a>\n\t<\/h3>\n\t

Birgitte Booij, Ph.D., is Vice President Product and Business development at SpinChip Diagnostics, a startup company developing a new state of the art platform for in vitro diagnostics aimed at the Point of Care market.<\/p>\n

Booij holds a PhD in biotechnology from the University of Cambridge and a masters\u2019 degree in chemistry from the University of Groningen.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Christopher_Ung_Histogenex_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Christopher_Ung_Histogenex_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Christopher_Ung_Histogenex_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Christopher_Ung_Histogenex_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Christopher_Ung_Histogenex_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Christopher_Ung_Histogenex_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Christopher_Ung_Histogenex_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32561″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/christopher-ung\/olympus-digital-camera-3\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Christopher_Ung_Histogenex_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"16","credit":"","camera":"E-1","caption":"OLYMPUS DIGITAL CAMERA","created_timestamp":"1232457129","copyright":"","focal_length":"36","iso":"100","shutter_speed":"0.0125","title":"OLYMPUS DIGITAL CAMERA","orientation":"1"}” data-image-title=”OLYMPUS DIGITAL CAMERA” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Christopher_Ung_Histogenex_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Christopher_Ung_Histogenex_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tChristopher Ung\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Chief Business Officer at HistogeneX<\/h5>\n

\n\t\t\t\n\tDigital Pathology in Immuno-Oncology – A Roadmap for Clinical Development\n\t\t\t<\/a>\n\t<\/h3>\n\t

Mr. Christopher Ung led the global development and commercialization efforts of HercepTest\u2122 and pharmDx EGFR companion diagnostic assays. He continues to lead and implement global biomarker strategies for drug development and companion diagnostic projects. He has set up CAP, CLIA laboratories in the US, Scotland, China, and Singapore, all of which are connected via a digital pathology WSI scanning and analysis platform.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Eric_Faulkner_Evidera_BioTech_Pharma_Summit_Profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Eric_Faulkner_Evidera_BioTech_Pharma_Summit_Profile_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Eric_Faulkner_Evidera_BioTech_Pharma_Summit_Profile_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Eric_Faulkner_Evidera_BioTech_Pharma_Summit_Profile_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Eric_Faulkner_Evidera_BioTech_Pharma_Summit_Profile_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Eric_Faulkner_Evidera_BioTech_Pharma_Summit_Profile_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Eric_Faulkner_Evidera_BioTech_Pharma_Summit_Profile_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32651″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/eric-faulkner\/eric_faulkner_evidera_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Eric_Faulkner_Evidera_BioTech_Pharma_Summit_Profile_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"5.6","credit":"","camera":"Canon EOS 6D","caption":"","created_timestamp":"1460736428","copyright":"","focal_length":"100","iso":"100","shutter_speed":"0.00625","title":"","orientation":"1"}” data-image-title=”Eric_Faulkner_Evidera_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Eric_Faulkner_Evidera_BioTech_Pharma_Summit_Profile_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Eric_Faulkner_Evidera_BioTech_Pharma_Summit_Profile_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tEric Faulkner\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President, Precision and Transformative Technology Solutions at at Evidera<\/h5>\n

\n\t\t\t\n\tHow are Critical Success Factors for Precision Medicine Acceptance and Uptake Changing as we Move into the Next Generation of Personalized Patient Care?\n\t\t\t<\/a>\n\t<\/h3>\n\t

Mr. Faulkner brings approximately 20 years of experience in the healthcare industry focusing on value demonstration, market access and commercialization of emerging health technologies. Mr. Faulkner is a recognized global thought leader in personalized medicine\/diagnostic, regenerative medicine, biopharmaceutical, and medical technology market access, with extensive publication and over 80 global panel sessions on these topics.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Gary_Gustavsen_Health_Advances_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Gary_Gustavsen_Health_Advances_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Gary_Gustavsen_Health_Advances_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Gary_Gustavsen_Health_Advances_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Gary_Gustavsen_Health_Advances_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Gary_Gustavsen_Health_Advances_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Gary_Gustavsen_Health_Advances_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32663″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/gary-gustavsen\/gary_gustavsen_health_advances_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Gary_Gustavsen_Health_Advances_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"Gary Gustavsen","camera":"","caption":"","created_timestamp":"1504274278","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Gary_Gustavsen_Health_Advances_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Gary_Gustavsen_Health_Advances_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Gary_Gustavsen_Health_Advances_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tGary Gustavsen\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Partner, Personalized Medicine at Health Advances<\/h5>\n

\n\t\t\t\n\tPartnership Strategy Evolution over the CDx Lifecycle\n\t\t\t<\/a>\n\t<\/h3>\n\t

Gary Gustavsen joined Health Advances in 2005 and leads its PrecisionMedicine Practice. A noted writer and workshop leader in the field of companion diagnostics and personalized medicine, his work focuses on commercialization strategy, indication prioritization, pricing and reimbursement strategy, system economics, and business development opportunities for both diagnostic and therapeutic clients.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Harry_Glorikian_Moneyball_IVD_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Harry_Glorikian_Moneyball_IVD_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Harry_Glorikian_Moneyball_IVD_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Harry_Glorikian_Moneyball_IVD_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Harry_Glorikian_Moneyball_IVD_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Harry_Glorikian_Moneyball_IVD_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Harry_Glorikian_Moneyball_IVD_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32614″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/harry-glorikian\/harry_glorikian_moneyball_ivd_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Harry_Glorikian_Moneyball_IVD_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"john soares","camera":"","caption":"","created_timestamp":"1341999939","copyright":"john soares 2012","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Harry_Glorikian_Moneyball_IVD_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Harry_Glorikian_Moneyball_IVD_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Harry_Glorikian_Moneyball_IVD_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tHarry Glorikian\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
CEO, Sr. Executive, Board Director, Author, MoneyBall Medicine & Commercialization of Novel IVDs\u200b<\/h5>\n

\n\t\t\t\n\tThe changing face of healthcare: dawn of individualized medicine\n\t\t\t<\/a>\n\t<\/h3>\n\t

Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends. He holds four US patents in telecommunications, and has others pending.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Henrik_Winther_Immunovia_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Henrik_Winther_Immunovia_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Henrik_Winther_Immunovia_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Henrik_Winther_Immunovia_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Henrik_Winther_Immunovia_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Henrik_Winther_Immunovia_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Henrik_Winther_Immunovia_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32639″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/henrik-winther\/henrik_winther_immunovia_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Henrik_Winther_Immunovia_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Henrik_Winther_Immunovia_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Henrik_Winther_Immunovia_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Henrik_Winther_Immunovia_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tHenrik Winther\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Senior Vice President, Precision Diagnostics at Immunovia AB<\/h5>\n

\n\t\t\t\n\tStrategic Partnerships for CDx \u2013 Challenges and Opportunities\n\t\t\t<\/a>\n\t<\/h3>\n\t

Henrik Winther has been at the forefront of companion diagnostics for over 10 years. He brings solid experiences within R&D, business development, regulatory, manufacturing and commercialization of IVD products.<\/p>\n

From 2006, Henrik was R&D Director at Dako A\/S and spearheaded the design responsibility of their most successful product, the HercepTest CDx assay, and later was Head of Dako Business Development and involved in the acquisition of Dako by Agilent Technologies.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jakob_Unilabs_2_BioTech_Pharma_summit_profile.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jakob_Unilabs_2_BioTech_Pharma_summit_profile-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jakob_Unilabs_2_BioTech_Pharma_summit_profile-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jakob_Unilabs_2_BioTech_Pharma_summit_profile-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jakob_Unilabs_2_BioTech_Pharma_summit_profile-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jakob_Unilabs_2_BioTech_Pharma_summit_profile-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jakob_Unilabs_2_BioTech_Pharma_summit_profile-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32550″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/jakob-gjorret\/jakob_unilabs_2_biotech_pharma_summit_profile\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jakob_Unilabs_2_BioTech_Pharma_summit_profile.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"Jakob Gju00f8rret","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Jakob_Unilabs_2_BioTech_Pharma_summit_profile” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jakob_Unilabs_2_BioTech_Pharma_summit_profile-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jakob_Unilabs_2_BioTech_Pharma_summit_profile-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJakob Gj\u00f8rret\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Managing Director, Unilabs Denmark<\/h5>\n

\n\t\t\t\n\tLab service component in development and commercialization of drug associated diagnostic services\n\t\t\t<\/a>\n\t<\/h3>\n\t

Jakob Gj\u00f8rret is Managing Director, CEO for Unilabs Denmark in Copenhagen and is also leading Unilabs Group initiative for Serving Pharma, with efforts to combine and align capabilities for bioanalysis in drug development and commercializing drug associated diagnostic services. Before joining Unilabs in 2017 he was Director of Alliance Management within Agilent\u2019s Companion Diagnostics division.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jeffrey_Jones_SkylineDx_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jeffrey_Jones_SkylineDx_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jeffrey_Jones_SkylineDx_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jeffrey_Jones_SkylineDx_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jeffrey_Jones_SkylineDx_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jeffrey_Jones_SkylineDx_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jeffrey_Jones_SkylineDx_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32602″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/jeffrey-jones\/jeffrey_jones_skylinedx_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jeffrey_Jones_SkylineDx_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Jeffrey_Jones_SkylineDx_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jeffrey_Jones_SkylineDx_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Jeffrey_Jones_SkylineDx_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJeffrey Jones\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Executive Vice President, Commercial Operations at SkylineDx<\/h5>\n

\n\t\t\t\n\tOvercoming challenges in the global commercialization of novel biomarkers\n\t\t\t<\/a>\n\t<\/h3>\n\t

Mr. Jones joined SkylineDx as the Executive Vice President, Commercial Operations in August 2015. He brings more than twenty-five years of experience to SkylineDx as a proven commercial leader in the global in-vitro diagnostics industry.<\/p>\n

Prior to that, Jeff worked for several Fortune 500 companies to include: Abbott Diagnostics, Bayer Healthcare, and Quest Diagnostics where he held both regional and global positions of increasing responsibility. Jeff received his undergraduate degree from UCLA.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ju\u0308rgen_Doppke_Thermo_Fisher_Scientific_BioTech_Pharma_Summit_Profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ju\u0308rgen_Doppke_Thermo_Fisher_Scientific_BioTech_Pharma_Summit_Profile_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ju\u0308rgen_Doppke_Thermo_Fisher_Scientific_BioTech_Pharma_Summit_Profile_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ju\u0308rgen_Doppke_Thermo_Fisher_Scientific_BioTech_Pharma_Summit_Profile_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ju\u0308rgen_Doppke_Thermo_Fisher_Scientific_BioTech_Pharma_Summit_Profile_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ju\u0308rgen_Doppke_Thermo_Fisher_Scientific_BioTech_Pharma_Summit_Profile_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ju\u0308rgen_Doppke_Thermo_Fisher_Scientific_BioTech_Pharma_Summit_Profile_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32567″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/jurgen-doppke\/ju%cc%88rgen_doppke_thermo_fisher_scientific_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ju\u0308rgen_Doppke_Thermo_Fisher_Scientific_BioTech_Pharma_Summit_Profile_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"1510241144","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Ju\u0308rgen_Doppke_Thermo_Fisher_Scientific_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ju\u0308rgen_Doppke_Thermo_Fisher_Scientific_BioTech_Pharma_Summit_Profile_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Ju\u0308rgen_Doppke_Thermo_Fisher_Scientific_BioTech_Pharma_Summit_Profile_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJ\u00fcrgen Doppke\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director Business Development Diagnostics Partnering at Thermo Fisher Scientific<\/h5>\n

\n\t\t\t\n\tTargeted Next Generation Sequencing Panels for the Rapid Development of CDx in Oncology\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. J\u00fcrgen Doppke, received his PhD from the Ruhr University in Bochum in cooperation with Boehringer Ingelheim. Subsequently he gained 15 Years Experience in various Roles as Sales- and Product Specialist, Field Application Scientist and Product Line Leader for Lab Automation, Research Instrumentation and High Content Screening Products for Companies like Beckman Coulter, Molecular Devices and Perkin Elmer.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32555″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/martina-kaufmann\/martina-kaufmann-2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"6.3","credit":"liegen bei der Bildautorin","camera":"NIKON D3X","caption":"Martina Kaufmann;nDu00f6bele Design – Wiesbaden","created_timestamp":"1348580020","copyright":"www.katrindenkewitz.de","focal_length":"105","iso":"200","shutter_speed":"0.00625","title":"Martina Kaufmann","orientation":"1"}” data-image-title=”Martina Kaufmann” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMartina Kaufmann\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Managing Director at Martina Kaufmann Strategic Consulting<\/h5>\n

\n\t\t\t\n\tCompanion diagnostics \u2013 recent advances and future perspectives\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Martina Kaufmann, Managing Director at Martina Kaufmann Strategic Consulting (www.mk-stracon.com<\/a>) has 15+ years industry experience in the field of personalized medicine \u2013 from biomarker validation, companion diagnostics development to implementation of such products in the market.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Morteza_Minaee_Guardant_Health_BioTech_Pharma_Summit_Profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Morteza_Minaee_Guardant_Health_BioTech_Pharma_Summit_Profile_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Morteza_Minaee_Guardant_Health_BioTech_Pharma_Summit_Profile_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Morteza_Minaee_Guardant_Health_BioTech_Pharma_Summit_Profile_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Morteza_Minaee_Guardant_Health_BioTech_Pharma_Summit_Profile_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Morteza_Minaee_Guardant_Health_BioTech_Pharma_Summit_Profile_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Morteza_Minaee_Guardant_Health_BioTech_Pharma_Summit_Profile_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32590″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/morteza-minaee\/morteza_minaee_guardant_health_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Morteza_Minaee_Guardant_Health_BioTech_Pharma_Summit_Profile_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Morteza_Minaee_Guardant_Health_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Morteza_Minaee_Guardant_Health_BioTech_Pharma_Summit_Profile_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Morteza_Minaee_Guardant_Health_BioTech_Pharma_Summit_Profile_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMorteza Minaee\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President of Regulatory Affairs at Guardant Health<\/h5>\n

\n\t\t\t\n\tRegulatory considerations for Next Generation Sequencing (NGS)-based circulating tumor DNA (ctDNA) as biomarker candidates into companion diagnostics\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Morteza Minaee has more than 25 years of experience in the FDA-regulated medical devices and global diagnostic industry leading regulatory, quality-systems, and clinical-affairs organizations.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Nick_Zhang_Qiagen_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Nick_Zhang_Qiagen_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Nick_Zhang_Qiagen_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Nick_Zhang_Qiagen_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Nick_Zhang_Qiagen_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Nick_Zhang_Qiagen_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Nick_Zhang_Qiagen_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32621″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/nick-zhang\/nick_zhang_qiagen_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Nick_Zhang_Qiagen_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"4","credit":"Evan Burrows","camera":"Canon EOS-1Ds Mark III","caption":"","created_timestamp":"1224235652","copyright":"u00a9 2008 Novartis Institutes for BioMedical Research, Inc. All rights reserved.","focal_length":"96","iso":"320","shutter_speed":"0.033333333333333","title":"","orientation":"1"}” data-image-title=”Nick_Zhang_Qiagen_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Nick_Zhang_Qiagen_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Nick_Zhang_Qiagen_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tNick Zhang\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Chairman and CEO at QIAGEN (Suzhou) Translational Medicine Co. Ltd.<\/h5>\n

\n\t\t\t\n\tBiomarker and CDx – the first half of Precision Medicine\n\t\t\t<\/a>\n\t<\/h3>\n\t

With over 25 years of drug R&D experience and years of experience in translational and diagnostics, Nick is now the board chairman and CEO for QIAGEN (Suzhou) Translational Medicine Co. Ltd. that provides an integrated technology platform for biomarker, companion diagnostics development and clinical testing for precision medicine.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Docherty_Hologic_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Docherty_Hologic_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Docherty_Hologic_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Docherty_Hologic_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Docherty_Hologic_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Docherty_Hologic_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Docherty_Hologic_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32657″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/paul-docherty\/paul_docherty_hologic_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Docherty_Hologic_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Paul_Docherty_Hologic_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Docherty_Hologic_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Docherty_Hologic_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tPaul Docherty\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Relationship and Alliance Management at Hologic<\/h5>\n

\n\t\t\t\n\tThe development of Biomarkers to Diagnostic products\n\t\t\t<\/a>\n\t<\/h3>\n\t

Paul has worked for pharma\/biotech and services companies since completing his post-doctoral studies in the late 1990s.<\/p>\n

For the last 5 years he has worked on Personalised Healthcare and CDx partnerships and projects which has led to an in depth understanding of the relationships between the contract provider and acceptor, enabling him to engage and empathise whether for transactional business or strategic partnerships.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Whittaker_hvivo_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Whittaker_hvivo_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Whittaker_hvivo_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Whittaker_hvivo_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Whittaker_hvivo_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Whittaker_hvivo_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Whittaker_hvivo_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32627″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/paul-whittaker\/paul_whittaker_hvivo_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Whittaker_hvivo_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Paul_Whittaker_hvivo_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Whittaker_hvivo_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Whittaker_hvivo_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tPaul Whittaker\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President, Discovery Research at hVIVO<\/h5>\n

\n\t\t\t\n\tUtilising human challenge studies to accelerate the development of new therapies for respiratory disease\n\t\t\t<\/a>\n\t<\/h3>\n\t

Currently Vice President, Discovery Research at hVIVO (formerly RetroScreen Virology Ltd) with responsibility for strategic direction and leadership of scientific activities aimed at identifying and developing drug targets and biomarkers for respiratory disease.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Robert_Hawkins_University_Manchester_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Robert_Hawkins_University_Manchester_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Robert_Hawkins_University_Manchester_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Robert_Hawkins_University_Manchester_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Robert_Hawkins_University_Manchester_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Robert_Hawkins_University_Manchester_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Robert_Hawkins_University_Manchester_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32578″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/robert-hawkins\/robert_hawkins_university_manchester_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Robert_Hawkins_University_Manchester_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Robert_Hawkins_University_Manchester_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Robert_Hawkins_University_Manchester_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Robert_Hawkins_University_Manchester_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tRobert Hawkins\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Cancer Research UK Professor at the University of Manchester<\/h5>\n

\n\t\t\t\n\tAdoptive cell therapy for cancer using both natural and engineered T-cells\n\t\t\t<\/a>\n\t<\/h3>\n\t

Robert Hawkins is Cancer Research UK Professor at the University of Manchester and Christie Hospital. In addition to clinical training he was an MRC Research Fellow with Dr Greg Winter and Dr Cesar Milstein at the MRC laboratory of Molecular Biology in Cambridge.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Rohit_Nambisan_Treato_NeuroLex_Dx_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Rohit_Nambisan_Treato_NeuroLex_Dx_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Rohit_Nambisan_Treato_NeuroLex_Dx_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Rohit_Nambisan_Treato_NeuroLex_Dx_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Rohit_Nambisan_Treato_NeuroLex_Dx_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Rohit_Nambisan_Treato_NeuroLex_Dx_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Rohit_Nambisan_Treato_NeuroLex_Dx_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32669″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/rohit-nambisan\/rohit_nambisan_treato_neurolex_dx_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Rohit_Nambisan_Treato_NeuroLex_Dx_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Rohit_Nambisan_Treato_NeuroLex_Dx_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Rohit_Nambisan_Treato_NeuroLex_Dx_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Rohit_Nambisan_Treato_NeuroLex_Dx_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tRohit Nambisan\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
SVP Product Strategy & Partner Integration at Treato & Product Advisor at Neurolex Diagnostics<\/h5>\n

\n\t\t\t\n\tPatient Perspectives on Diagnostics & Testing\n\t\t\t<\/a>\n\t<\/h3>\n\t

Rohit\u2019s interests lie at the intersection of healthcare and technology. As the SVP, Product Strategy & Partner Integration at Treato, he manages Treato\u2019s Product & Innovation portfolio through bridging technological solutions and market need. Additionally, Rohit is the Product Advisor to NeuroLex Dx, a startup developing voice-based diagnostics for mental health disorders.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Stefan_Mu\u0308llner_fundamenta_Life_Science_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Stefan_Mu\u0308llner_fundamenta_Life_Science_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Stefan_Mu\u0308llner_fundamenta_Life_Science_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Stefan_Mu\u0308llner_fundamenta_Life_Science_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Stefan_Mu\u0308llner_fundamenta_Life_Science_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Stefan_Mu\u0308llner_fundamenta_Life_Science_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Stefan_Mu\u0308llner_fundamenta_Life_Science_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32585″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/stefan-mullner\/stefan_mu%cc%88llner_fundamenta_life_science_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Stefan_Mu\u0308llner_fundamenta_Life_Science_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Stefan_Mu\u0308llner_fundamenta_Life_Science_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Stefan_Mu\u0308llner_fundamenta_Life_Science_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Stefan_Mu\u0308llner_fundamenta_Life_Science_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tStefan M\u00fcllner\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
General Manager & Partner at fundamenta Life Science GmbH.<\/h5>\n

\n\t\t\t\n\tOptions for biomarker based patient stratification in NON-ONCOLOGY clinical development\n\t\t\t<\/a>\n\t<\/h3>\n\t

Stefan M\u00fcllner, a chemist by training, did his Ph.D. thesis in protein biochemistry and postdoc in molecular biology. During his long time as CEO of Protagen AG, he grew the company into the global technology leader in blood based patient stratification to enable novel autoimmune therapy.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Susanne_Munksted_Agilent_Technologies_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Susanne_Munksted_Agilent_Technologies_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Susanne_Munksted_Agilent_Technologies_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Susanne_Munksted_Agilent_Technologies_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Susanne_Munksted_Agilent_Technologies_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Susanne_Munksted_Agilent_Technologies_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Susanne_Munksted_Agilent_Technologies_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32645″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/susanne-munksted\/susanne_munksted_agilent_technologies_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Susanne_Munksted_Agilent_Technologies_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"5.6","credit":"","camera":"NIKON D7000","caption":"","created_timestamp":"1363613188","copyright":"","focal_length":"50","iso":"400","shutter_speed":"0.008","title":"","orientation":"1"}” data-image-title=”Susanne_Munksted_Agilent_Technologies_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Susanne_Munksted_Agilent_Technologies_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Susanne_Munksted_Agilent_Technologies_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tSusanne Munksted\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Global Commercial Director, CDx Commercial Management at Agilent Technologies<\/h5>\n

\n\t\t\t\n\tThe PD-L1 CDx Commercialization Journey\n\t\t\t<\/a>\n\t<\/h3>\n\t

Susanne Munksted holds a Master of Science in Pharmaceutical Sciences from The Royal Danish University of Pharmacy, followed by an Executive CBA (Certificate in Business Administration) and a number of Diplomas in People Management and Sales and Marketing. She worked +10 years in various International Commercial roles in the pharmaceutical industry before joining Agilent (before Dako) in 2009 and is now Global Commercial Director for Companion Diagnostics.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Our Speakers (A-Z) Ali Ardakani Managing Director at Novateur Ventures Inc. Companion Diagnostics: a guide to cure? For the past 18 years, Ali Ardakani has been pivotal in start-up and development of several biotech companies, drugs and medical devices, for which he has raised over $100 M USD in private and grant financing. Most recently,…<\/p>\n","protected":false},"author":1,"featured_media":32540,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-32539","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nCompanion Diagnostics & Biomarkers 2017 Speakers • BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"The BioTech Pharma Summit is proud to present the Companion Diagnostics & Biomarkers 2017 . This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Companion Diagnostics & Biomarkers 2017 Speakers • BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"The BioTech Pharma Summit is proud to present the Companion Diagnostics & Biomarkers 2017 . This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-18T12:23:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/CDx_Biomarkers_BioTech_Pharma_Summit_2017.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1152\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/\",\"name\":\"Companion Diagnostics & Biomarkers 2017 Speakers • BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/CDx_Biomarkers_BioTech_Pharma_Summit_2017.png\",\"datePublished\":\"2020-07-28T11:07:41+00:00\",\"dateModified\":\"2021-03-18T12:23:49+00:00\",\"description\":\"The BioTech Pharma Summit is proud to present the Companion Diagnostics & Biomarkers 2017 . This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/CDx_Biomarkers_BioTech_Pharma_Summit_2017.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/CDx_Biomarkers_BioTech_Pharma_Summit_2017.png\",\"width\":1920,\"height\":1152},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Companion Diagnostics & Biomarkers 2017 Speakers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow's healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Companion Diagnostics & Biomarkers 2017 Speakers • BioTech Pharma Summit","description":"The BioTech Pharma Summit is proud to present the Companion Diagnostics & Biomarkers 2017 . This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/","og_locale":"en_US","og_type":"article","og_title":"Companion Diagnostics & Biomarkers 2017 Speakers • BioTech Pharma Summit","og_description":"The BioTech Pharma Summit is proud to present the Companion Diagnostics & Biomarkers 2017 . This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-18T12:23:49+00:00","og_image":[{"width":1920,"height":1152,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/CDx_Biomarkers_BioTech_Pharma_Summit_2017.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/","name":"Companion Diagnostics & Biomarkers 2017 Speakers • BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/CDx_Biomarkers_BioTech_Pharma_Summit_2017.png","datePublished":"2020-07-28T11:07:41+00:00","dateModified":"2021-03-18T12:23:49+00:00","description":"The BioTech Pharma Summit is proud to present the Companion Diagnostics & Biomarkers 2017 . This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/CDx_Biomarkers_BioTech_Pharma_Summit_2017.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/CDx_Biomarkers_BioTech_Pharma_Summit_2017.png","width":1920,"height":1152},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Companion Diagnostics & Biomarkers 2017 Speakers"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow's healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32539","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=32539"}],"version-history":[{"count":6,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32539\/revisions"}],"predecessor-version":[{"id":36050,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32539\/revisions\/36050"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/32540"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=32539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}